The U.S. Food and Drug Administration has approved several inhibitors of the PD-1/PD-L1 axis, including nivolumab, pembrolizumab, atezolizumab and durvalumab as monotherapy or in combination with platinum-based chemotherapy for a subset of patients with NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.